Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

>.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jacobs Automotive, a group of car dealerships headquartered in ... Blood Center and offering free oil change coupons for participation ... Jan. 18 at the Bill Jacobs Cadillac and Chevrolet location ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto annual ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... of Angel Soft website Madison, Wis. Imagine, says ... that you actually want to watch it again and again. ... Soft toilet paper by international tissue and paper manufacturer Georgia-Pacific. ... asks him what he is doing," Ramsey told a crowd ...
... exceeded expectations, reaching $3.6 billion in 2002, according to a new ... 2005. , ,In 2002, the state ranked 20 th ... in academic R&D spending. , ,"You'd be hard-pressed to find ... few years," said David Ward, president of NorthStar Economics ...
... has announced the release of Centricity Physician Office ... for physicians that extends the functionality of Centricity Physician ... , , Centricity Physician Office Mobile ... and schedules and to capture charges from any location. ...
Cached Biology Technology:Consumer "engagement" stressed at e-Business seminar 2Consumer "engagement" stressed at e-Business seminar 3New report says Wisconsin R&D spending exceeding expectations 2
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized ... considered it to be essentially an affliction of primary motor ... that control muscle movement. , But in a new study ... Neuron , a team of scientists at the University of ...
(Date:4/16/2014)... director of the Physical Biosciences Division of Lawrence Berkeley ... recognized as a leading authority on the evolutionary design ... to systems and synthetic biology, has been named one ... Award by U.S. Energy Secretary Ernest Moniz. The E.O. ...
Breaking Biology News(10 mins):For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3
... University of Wisconsin School of Medicine and Public Health ... taking part in a novel clinical trial investigating if ... of severe coronary artery disease. , The trial, just ... in the Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia (ACT34-CMI) ...
... but also too much iron is bad for our ... where it can lead to organ failure and even ... Researchers from the Innsbruck Medical University, the University of ... now made a surprising discovery that may lead to ...
... play a pivotal role in the inception of Darwin’s theory ... their significance when he collected them during his voyage on ... predict the impact the vast amount of marine microbial DNA ... J. Craig Venter, Ph.D., and his team ?will have on ...
Cached Biology News:UW launches study testing adult stem cells for heart damage repair 2UW launches study testing adult stem cells for heart damage repair 3Putting an old drug to a new use 2Darwin's famous finches and Venter's marine microbes 2Darwin's famous finches and Venter's marine microbes 3Darwin's famous finches and Venter's marine microbes 4Darwin's famous finches and Venter's marine microbes 5
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Mouse Anti-Human MCAF-(MCP-1)...
LTBP-1 (E-20)...
Biology Products: